Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).

被引：1
|
作者：
Marar, Mallika [1 ]
Long Qi [1 ]
Mamtani, Ronac [1 ]
Narayan, Vivek [1 ]
Vapiwala, Neha [1 ]
Parikh, Ravi Bharat [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer.
    Marar, Mallika
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    [J]. APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [4] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [5] Racial disparities in metastatic castrate-resistant prostate cancer (mCRPC): Evidence from the Veterans Health Administration (VHA).
    Halwani, Ahmad
    Rasmussen, Kelli M.
    Patil, Vikas
    Burningham, Zachary
    Narayanan, Sujata
    Lin, Shih-Wen
    Carroll, Susheela
    Hsu, Ling-I
    Graff, Julie N.
    Dreicer, Robert
    Gupta, Sumati
    Low, Clarke
    Sauer, Brian C.
    [J]. CANCER RESEARCH, 2018, 78 (16) : 54 - 54
  • [6] Retreatment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone
    Leibowitz-Amit, Raya
    Alimohamed, Nimira
    Vera-Badillo, Francisco E.
    Seah, Jo-An
    Templeton, Arnoud J.
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    [J]. PROSTATE, 2014, 74 (14): : 1462 - 1464
  • [7] Abiraterone acetate with prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study.
    del Alba, Arancha Gonzalez
    Puente, Javier
    Sala, Nuria
    Mendez, Maria Jose
    Pinto, Alvaro
    Sanchez, Angel Rodriguez
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Heo, Mi Hwa
    Park, Se Hoon
    Kim, Hee Kyung
    Cho, Jinhyun
    Kim, Youjin
    Lee, Hansang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer
    Francini, Edoardo
    Fiaschi, Anna Ida
    Petrioli, Roberto
    Francini, Filippo
    Bianco, Vincenzo
    Perrella, Armando
    Paganini, Giovanni
    Laera, Letizia
    Roviello, Giandomenico
    [J]. ANTI-CANCER DRUGS, 2014, 25 (04) : 472 - 477
  • [10] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345